MedX Health Corp.

lockPrivate Group

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™,...

people10 Members       (0)

Corporate Profile
Group Admins:
  • Thumb 8020 monitor 200 200  png
  • Thumb no photo
  • Thumb no photo
Request Membership


MedX Health Corp.

lockPrivateGroup

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAs......

people10 Members       (0)

Thumb 8020 monitor 200 200  png

8020 Admin

22 hours

8020 Admin posted a press release MedX Health and Sanitas Spain Announce a Large-Scale Skin Cancer Screening Initiative in Spain Using MedX's DermSecure(TM) Technology in MEDX HEALTH CORP.

MISSISSAUGA, Ontario


MedX Health Corp. (“MedX”) (TSX-V:MDX) announces that it has partnered with SANITAS, a specialist in healthcare and well-being services in Spain, to conduct a skin cancer screening initiative. According to recent studies, Spain, with its warm and sunny climate has experienced a 50% increase in skin cancer rates over the last decade. It is the most common form of cancer in women between the age of 25 and 29, followed by breast cancer, and the most common in men between the age of 30 and 35, ahead of lung and colon cancer.


MedX, with its Spanish distributor (OncoTech), has partnered with SANITAS, who will target twelve of SANITAS’s multi-national company customers, with up to 3,000 patient scans to be taken using MedX’s DermSecure™, to assess the benefits of such an initiative to SANITAS, its clients and the Spanish healthcare system. Upon completion, SANITAS will consider a significant expansion of this program. Dr. Miguel Marine Blanco, Director of Strategic Alliances for SANITAS commented, “With the increase in skin cancer rates in Spain we felt being able to offer our members skin cancer screening with the best screening technology available would be well received by our members.”


Sanitas offers its clients products and services adapted to people’s real needs at each stage of their lives through an integral healthcare model that includes: medical insurance, hospitals and multi-speciality centres, well-being centres, dental clinics, other health services and services for the care of the elderly. Sanitas forms part of Bupa, a leading international healthcare company, which serves over 15.7 million insurance policy holders, 15 million patients and 23,000 elderly people.


Mr. Frank Melendez, OncoTech’s President stated, “It is an honour to work with SANITAS and their multi-national customers. They truly wish to deliver the best possible care to their members which speaks to their success. We are looking forward to the results of this pilot and to further expand this program in the future.”


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com


About SANITAS


Sanitas is a specialist in healthcare and well-being services in Spain. It offers its clients products and services adapted to people’s real needs at each stage of their lives through an integral healthcare model that includes: medical insurance, hospitals and multi-speciality centres, well-being centres, dental clinics, other health services and services for the care of the elderly.


It has 10,859 employees; it has a medical team made up of over 40,000 specialists and 1,200 associated medical centres, in addition to its own service, formed by 4 hospitals, 20 multi-speciality medical centres, 16 well-being centres, 180 dental clinics, 47 homes for the elderly, 17 of them with day centre services and 5 independent day centres.


Sanitas forms part of Bupa, a leading international healthcare company, which serves over 15.7 million insurance policy holders, 15 million patients and 23,000 elderly people.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.


View source version on businesswire.com: https://www.businesswire.com/news/home/20190617005235/en/



Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229



!
Thumb 8020 media relations

Media Relations posted an update in MEDX HEALTH CORP.

2 months

Mike Druhan on the competitive advantages of MedX's (TSXV: MDX) skin cancer diagnosis technology

!
Thumb 8020 monitor 200 200  png

8020 Admin

2 months

8020 Admin posted a press release MedX Health Corp. Announces Non-Brokered Private Placement in MEDX HEALTH CORP.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it has obtained Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 15,625,000 units at $0.16 per unit (“Unit”), to raise up to $2,500.000. Each Unit will be comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.25, exercisable for a period of two years from the date of issue. Closing of the Placement, which will take place in tranches, will be subject to receipt of subscriptions and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. Qualified Agents may receive commissions in respect of subscriptions introduced by them by way of cash equal to 6% of funds so introduced, and issuance of agent’s warrants (“Agent’s Warrant(s)”) equal in number to 6% of the number of units so subscribed for. Each Agent’s Warrant, which is non-transferable, will be exercisable to acquire one Unit at $0.16 per Unit, at any time during the period of two years following the Closing. The first Closing of this private placement has taken place on April 26, 2019, to raise $282,600 by issuance of 1,766,250 Units. In connection with the first Closing, a cash commission of $12,960 was paid and 79,350 Agent’s Warrants were issued.


Following this Closing, MedX has 139,782,651 common shares issued and outstanding.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.




Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229


Media Relations
Deborah Thompson
dthompson@medxhealth.com
416-918-9551


!
Thumb 8020 monitor 200 200  png

8020 Admin

2 months

8020 Admin posted a press release MedX Health Signs Exclusive Distribution Agreement to Launch DermSecure(TM) in Brazil, where Skin Cancer is Prevalent in MEDX HEALTH CORP.

MISSISSAUGA, Ontario


MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that it has signed an Exclusive Distribution Agreement with CBD Vida (“Vida”), to launch a comprehensive, ease-of-access skin scanning/assessment program throughout Brazil, using MedX’s DermSecureTM Telemedicine platform.


This exclusive distribution agreement is a natural progression of the earlier Memorandum of Understanding with Vida “because their reach in the Brazilian marketplace is robust and extensive,” said Scott Spearn, President & CEO of MedX. Mr. Spearn said that Vida has agreed to pay for all regulatory, marketing and distribution expenses related to the launch. Mr. Spearn also noted that the agreed performance levels on the part of Vida further reinforce their commitment to the commercial success of this agreement.


“Vida is 100% committed to this innovative screening platform. There are almost 212 million Brazilian people, where skin cancer is the most common form of cancer,” said Camata Candello, Vida’s CEO. There were over 100,000 cases of skin cancer diagnosed in Brazil between 2016 and 2017, and almost 6,000 were melanomas, the most aggressive form of the disease that has a high mortality rate. “This cancer does not need to be lethal and can be prevented through early detection. I believe this is a game changer. Brazil is a huge market opportunity for us,” continued Mr. Candello.


“We are always looking for solutions that are innovative and meaningful to invest in; as well they must have a major impact on the Brazilian people we serve. I can genuinely say that MedX’s DermSecureTM meets those criteria, and then some,” said Camata Candello.


“MedX’s DermSecure TM is a perfect solution for early detection of skin cancer," he said. “We are deeply aligned with the largest distributors of hospital equipment in Brazil, we will be distributing throughout the national territory of Brazil, offering MedX’s rapid skin assessment technology to Public and Private Hospitals, Medical Clinics, Pharmacies, Dermatologists and Oncologists. We believe this technology will have a major impact on public health, and as such have implemented a marketing plan to provide the equipment to Brazil's public health network for a fee in order to speed the rate of deployment throughout Brazil,” stated Camata Candello, Vida’s CEO.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


About CBD Vida


The founders of CBD Vida Canada, combined with their CBD Vida LTDA partners in Brazil, form a partnership that brings decades of professional business development, training and experience. CBD Vida LTDA’s business relationships in Brazil are extensive and cover pharmaceuticals, medical clinics, and pharmacies, legal, regulatory, governmental, and private industry. These relationships provide a synergy between Brazil & Canada that will ensure expedited market entry for this life saving solution.


The partners understand the importance of Brazil on the world market, with it being the second largest importer of medical devices in the world. CBD Vida’s relationship with MedX and their rapid skin assessment solution, combined with their corporate & business experiences, will give the Brazilian population an opportunity to dramatically reduce the mortality rate currently being experienced by late the late detection skin cancer. CBD Vida LTDA has the capability and commitment to open the Brazilian market rapidly and help our fellow Brazilians with this preventable cancer.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.




Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229

Jean Guy Bourguignon, President and COO
CBD Vida Canada
613-406-6473

Media Relations
Deborah Thompson
416-918-9551



!
Thumb 8020 monitor 200 200  png

8020 Admin

4 months

8020 Admin posted a press release MedX Health Corp. Announces Private Label Distributor Agreement for Selected Therapeutic Laser Products with Richmar in US in MEDX HEALTH CORP.

MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed an agreement with Richmar, a Compass Health Brands Company, to manufacture and supply selected Private Label Laser and Light products to Richmar for the US rehabilitation market.


“We are very pleased that we are moving forward with Richmar. We believe their strong presence in the US, with a quality distribution network across the US will help MedX open channels to our Therapeutic Laser products and contribute to revenue growth in this large and important marketplace,” said Scott Spearn, President & CEO of MedX.


Mr. Spearn explained that MedX will provide under Private Label a number of its laser and SLD based products to Richmar, which is headquartered in Saint Louis, MO, with other facilities located throughout the US. “We are ramping up production and are set to begin delivering our specified reliable, high-quality, Therapeutic Laser products that service physicians and clinicians,” Mr. Spearn added. Target markets include chiropractors, physical therapists, athletic trainers, and other qualified healthcare professionals who wish to decrease pain and restore function to their patients.


According to a 2017 report from Grand View Research, the United States is experiencing an increasing prevalence of degenerative diseases, an expanding geriatric population, as well as a growing number of trauma patients; who will all require physical rehabilitation. “It is important to Richmar that we have the appropriate tools and technologies to assist these populations,” noted Ryan Moore, Senior Vice President, Therapy, at Richmar. “Our partnership with MedX will help ensure that we are equipped to provide clinicians with what they need to drive better outcomes and improve patients’ lives.”


About MedX Health Corp.


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


About Richmar


Since 1968, Richmar has provided clinicians with the means to treat musculoskeletal and soft tissue inflammation. A Compass Health Brands company, Richmar is a leading manufacturer and distributor of a diverse line of high-quality medical devices and accessories for the physical therapy, chiropractic, and athletic training markets. A relentless innovator, Richmar features a growing list of products which serve the needs of clinicians treating musculoskeletal and soft tissue disorders. Among Richmar's product portfolio are such modalities as electrotherapy, combination, laser, diathermy, ultrasound, and their corresponding consumables. Richmar's popular brands include Winner EVO Series™, HydraTherm™, HydraHeat™, TheraTouch®, AutoSound®, InTENSity®, StrengthTape®, and SubZero®. Visit richmarweb.com.


About Compass Health Brands


Compass Health Brands® manufactures and distributes a broad range of innovative and high-quality homecare, rehabilitation, light therapy and pain management products that enable consumers to live healthier, more independent lives. The company markets its products to both professional and consumer sectors. Consumer brands include Carex®, AccuRelief™, Apex®, TheraLite™, Bed Buddy®, STRENGTHTAPE® and TheraMed® and are sold through drugstore chains, drug wholesalers, mass merchants, and grocery retailers. Professional brands include ProBasics™, Roscoe Medical®, Meridian Medical®, InTENSity®, and Richmar® which are sold through a professional independent dealer/distributor network.




Scott Spearn, President & CEO, MedX
905 670 4428 ext 226


Media Relations
Deborah Thompson
DThompson@medxhealth.com
M: 416-918-9551


!
Thumb 8020 monitor 200 200  png

8020 Admin

5 months

8020 Admin posted a press release MedX Health Signs MOU to Launch DermSecure(TM) in Brazil in MEDX HEALTH CORP.

MISSISSAUGA, Ontario


MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed a Memorandum of Understanding with CBD Vida LTDA, who plans to launch an ease-of-access skin scanning/assessment program throughout Brazil, using MedX’s DermSecureTM. Telemedicine platform.


"There is a significant opportunity for MedX’s skin imaging technology in Brazil, as skin cancer is the most common type of cancer in Brazil,” stated Fabio Camata Candello, CBD Vida LTDA’s CEO. More than one hundred thousand new cases of skin cancer were recorded in Brazil between 2016 and 2017, according to the Brazilian Cancer Institute, and almost 6,000 were classified as melanoma, an aggressive form of the disease that can spread to other parts of the body. A recent study shows that Brazilian melanoma patients experienced a lower survival rate than the current worldwide average. The high prevalence of advanced cases reinforces the importance of local strategies to diagnose melanomas in the early stages, and to treat it definitively. “MedX’s DermSecureTM telemedicine platform and advanced SIAscopy imaging technology is a perfect solution for early detection," further noted Mr. Candello.


"CBD Vida LTDA’s experience in marketing medical devices and health solutions in the Brazilian market, as well as their deep connectivity with major pharmacies and medical clinics will be a big benefit as they enter into this large market, and we are delighted to be partnering with them,” noted Scott Spearn, President & CEO of MedX “


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


About CBD Vida LTDA


The founders of CBD Vida Canada, combined with their CBD Vida LTDA partners in Brazil form a partnership that brings decades of professional business development, training and experience. CBD Vida LTDA’s business relationships in Brazil are extensive and cover pharmaceuticals, medical clinics, and pharmacies, legal, regulatory, governmental, and private industry. These relationships provide a synergy between Brazil & Canada that will ensure expedited market entry for this life saving solution.


The partners understand the importance of Brazil on the world market, with it being the second largest importer of medical devices in the world. CBD Vida LTDA’s relationship with MDX Health and their rapid skin assessment solution, combined with their corporate & business experiences, will give the Brazilian population an opportunity to dramatically reduce the mortality rate currently being experienced by late the late detection skin cancer. CBD Vida LTDA has the capability and commitment to open the Brazilian market rapidly and help our fellow Brazilians with this preventable cancer.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.




Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229



!
Thumb 8020 monitor 200 200  png

8020 Admin

5 months

8020 Admin posted a press release MedX Health Corp. Announces Private Placement Closing in MEDX HEALTH CORP.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

January 29, 2019


MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX) announces that, pursuant to a non-brokered Private Placement Offering (the “Placement Offering”), it has completed an initial Closing of 2,962,500 Units on January 28, 2019, to raise $474,000 from accredited investors pursuant to a Private Placement Offering originally announced on November 23, 2018. Each Unit, priced at $0.16, comprises one fully paid common share and one share purchase warrant; each warrant entitles the holder to purchase one additional share at a price of $0.35 during the period up to three years from the closing date of the placement. The securities issued as a result of the Placement Offering will be restricted from trading for four months following each Closing. The Placement Offering is still open to subscribers, and further subscriptions may be accepted for further Closings. This Closing, and any further Closing of the Placement Offering, is subject to all relevant regulatory and other consents and approvals, including acceptance by the TSX Venture Exchange.


Following this Closing, MedX has 138,016,401 common shares issued and outstanding.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.




Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229


Media Relations
Deborah Thompson
dthompson@medxhealth.com
416-918-9551


!
Thumb year end 2017

Darren Stewart posted an update in MEDX HEALTH CORP.

5 months

Just thought I would share.

!
Thumb 8020 monitor 200 200  png

8020 Admin

6 months

8020 Admin posted a press release MedX Health Announces That Dr. Bruno Battistini, an Accomplished Canadian-Based Health Care Researcher Has Joined Its Medical Advisory Board in MEDX HEALTH CORP.

MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that Dr. Bruno Battistini, a Canadian-based health care researcher and medical business advisor has joined MedX’s Medical Advisory Board.


“While the members of our Medical Advisory Board to date are esteemed physicians and researchers specializing in skin cancer and other Dermatological conditions, Dr. Battistini complements the group by providing a breadth of experience dealing with policy, and bridging the gap with government, health care agencies and providers to gain access to Canadian markets,” said Scott Spearn, CEO of MedX. “His understanding of the dynamics in the Private/Public market will be of great benefit as we launch our skin assessment platform, DermSecure™, across Canada.”


“I am genuinely impressed with MedX’s complete solution for skin cancer screening,” noted Dr. Battistini. “Not only is the scanning technology so unique, offering the ability to image and highlight pathophysiology images below the skin, but the development of an internet-based platform that can provide widespread access to the public for fast and easy assessment will be a driver for reducing wait times and improved outcomes in a world that is experiencing increasing incidence of skin cancer and other skin conditions. There is no reason why MedX’s technology cannot assist our health care system and streamline the services to meet patients’ needs when it has already been implemented in other countries and working successfully for many years. The translation of knowledge and implementation of innovation is key to the sustainability of our healthcare system, considering our aging population,” noted Dr. Battistini


Dr. Battistini is an accomplished health care researcher, former professor of medicine, entrepreneur, senior executive and administrator whose background in pharmacology has resulted in a broad range of experience working with universities, government agencies and health foundations to understand how policies are developed such that companies can access markets with innovative products to improve the health care system and benefit patients and the general population. He has engaged with many Canadian companies, all in major and smaller provinces in guiding the development, acknowledgement, adoption and commercializing of products.


About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.




Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229


Media Relations
Deborah Thompson
dthompson@medxhealth.com
416-918-9551


!
Thumb 8020 monitor 200 200  png

8020 Admin

7 months

8020 Admin posted a press release MedX Signs MOU to Launch DermSecure(TM) in the Netherlands in MEDX HEALTH CORP.

MISSISSAUGA, Ontario



MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed a Memorandum of Understanding with a consortium of Dutch companies that will be launching an easy-access skin scanning/assessment program in the Netherlands, using MedX’s SIAscopy and DermSecureTM technologies. The consortium will integrate DermSecureTM with their existing platforms, which includes a suite of software applications used by a large majority of general practitioners in the Netherlands, and will build awareness campaigns through established healthcare initiatives and programs.


“The Dutch team is impressed with SIAscopy’s unique scanning technology, and the ability to seamlessly integrate our DermSecureTM platform into their suite of medical software applications that are used by more than 4,500 physicians in the Netherlands makes it a natural fit,” noted Scott Spearn, MedX’s President and CEO. “The broad reach of telemedicine from this many potential locations, with DermSecureTM providing the highest quality tools for the assessment by a team of trained Dermatologists, and the awareness built through their marketing relationships can enable the group to meet their objective of a truly national scanning/assessment program in the Netherlands, where there is a focus on cancer prevention and early screening.”


Pieter Severijns, Director of IvPG, one of the partners in this project and a company involved in programs and initiatives to improve healthcare in the Netherlands through the internet, noted “We have the ability through our programs to make people aware about the risks of melanoma, and allow those with higher risk or suspicious moles to easily access skin scanning and assessment by our top Dermatologists using DermSecureTM, through the large network of scanning centres that will be available to them.”


MedX will be working during the coming months to integrate its platform with those of its partners, while physicians are recruited to include DermSecureTM and MedX’s SIAscopy devices in their practices, and selected Dermatologists trained to provide timely assessment.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.


View source version on businesswire.com: https://www.businesswire.com/news/home/20181127005308/en/



Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229


Media Relations
Deborah Thompson
dthompson@medxhealth.com
416-918-9551



!
Thumb 8020 monitor 200 200  png

8020 Admin

7 months

8020 Admin posted a press release MedX Launches Strategic Artificial Intelligence Initiative in MEDX HEALTH CORP.

MISSISSAUGA, Ontario 



MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it is initiating the development of an Artificial Intelligence Engine with leading dermatologists and its technology partner, Blanc Labs, that will work in conjunction with its existing DermSecureTM screening platform. MedX has an opportunity to leverage Artificial Intelligence to create a unique assessment support tool allowing Dermatologists to more accurately assess suspicious moles and lesions from remote locations.


MedX’s advanced SIAscopy imaging technology lends itself to AI because of the specialized image capture above and below the skin’s surface. “SIAscopy is the only imaging technology that provides a dermascopic image along with four additional proprietary pathophysiology views 2 mm below the skin’s surface, produced in a consistent format, and we believe this large amount of data will increase the accuracy of our AI engine” said Scott Spearn, MedX’s President and CEO.


MedX has been working closely with its Scientific Medical Advisory Board (“SMAB”) to launch an AI strategy that will complement DermSecureTM and current assessment protocols. Dr. Trevor Champagne commented, “MedX has got the AI questions right. The question that AI needs to address is not what is a melanoma, but what is not a melanoma? What do we need to concentrate on with our biopsies and diagnosis? What can we safely exclude from this pool of potentially dangerous lesions? MedX’s thinking around AI is extremely important and I look forward to collaborating with them on this important advancement in the field of Dermatology.”


Dr. Joe Walls, also on MedX’s SMAB further noted “I wrote my thesis on SIAscopy and have been deeply involved in analyzing SIAscopic images in my professional practice. I think the advanced standardized images that SIAscopy produces will deeply enhance the AI process. AI only works when you have quality input and SIAscopy produces unique images not found in other imaging technologies,” noted Dr. Walls.


MedX looks forward to taking the next step with Blanc Labs on this important strategic initiative. “Adding AI features to the DermSecureTM platform is a natural evolution for this advanced medical imaging solution,” noted Dariush Zomorrodi, Blanc Lab’s Chief Innovation Officer, who has been collaborating with MedX on the development of DermSecureTM. “We will apply Machine Learning technology to a collection of images and diagnostic data. With the increase of data size, over time, the Deep Learning algorithm will enable the platform to deliver a highly accurate assessment tool to Dermatologists, and we are very excited to continue innovating with MedX, pushing the boundaries, and making an impact on the early detection of skin cancer.”


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.




Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229


Media Relations
Deborah Thompson
dthompson@medxhealth.com
416-918-9551



!
Thumb 8020 monitor 200 200  png

8020 Admin

8 months

8020 Admin posted a press release MedX Health Announces That Dr. Eggert Stockfleth, Director of the University Department of Dermatology at St. Josef-Hospital in Bochum, Germany Has Joined Its Medical Advisory Board in MEDX HEALTH CORP.

MISSISSAUGA, Ontario



MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that Dr. Eggert Stockfleth, Director of the University Department of Dermatology at St. Josef-Hospital in Bochum, Germany has agreed to join MedX’s Medical Advisory Board. Dr. Stockfleth was previously the Director of the Skin Cancer Center in Berlin.


“The addition of Dr. Stockfleth to our Medical Advisory Board completes our group of highly accomplished physicians from around the world. They are respected thought leaders located in our targeted markets. We are very fortunate to have access to Dr. Stockfleth’s knowledge and expertise,” said Scott Spearn, CEO of MedX.


“MedX’s non-invasive skin cancer scanning technology is ground-breaking and I am honored to be a member of such an esteemed group of physicians,” Dr. Stockfleth said. “I see first-hand how MedX’s technology is a game-changer in early detection of skin cancers,” he added. He noted that his clinic in Bochum receives in excess of 800 calls per day with respect to dermatological issues and has a capacity to handle only about half of the inquiries.


Dr. Stockfleth’s research on dermatology, oncology and in particular, skin cancer, has been extensively published in peer-reviewed journals. He has contributed to the Journal of Infectious Diseases, International Journal of Cancer, Journal of Investigative Dermatology and The Lancet. He is also the former European President of Skin Care in Organ Transplant Patients Network (SCOPE). In 2008 he was one of the founders of the European Skin Cancer Foundation, which assists in developing and providing standardized treatments on a European level. Dr. Stockfleth graduated from the University of Hamburg and is a Jung-Foundation scholar.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.




MedX Health Corp
Scott Spearn, 905-670-4428 ext 229
President and CEO
or
Media Relations
Deborah Thompson, 416-918-9551
dthompson@medxhealth.com



!
Thumb 8020 monitor 200 200  png

8020 Admin

9 months

8020 Admin posted a press release MedX Launches Its DermSecure™ Telemedicine Platform in MEDX HEALTH CORP.

MISSISSAUGA, Ontario--(BUSINESS WIRE)--September 4, 2018--MedX Health Corp. (“MedX”) (TSX-V:MDX) announced today that it is launching
DermSecure™, its telemedicine platform, in six Ontario clinics. MedX will begin rolling out DermSecure™ across Ontario and subsequently Canada while
finalizing its introduction into a number of international markets.


It is currently working on a DermSecure™ roll-out with its Spanish distribution partner as well as plans for the US, Mexico, and the Netherlands. MedX’s DermSecure™ has been built to the leading data repository standards to allow for integrationwith Electronic Medical Record (EMR’s) systems. Its development roadmap includes the addition of features and functions to the DermSecure™ platformthat will be released on a regular basis.


“DermSecure™ is a secure telemedicine platform, coupled with MedX’s innovative imaging technology, SIAscopy, that will provide dermatologists and
patients access to the most advanced mole and lesion rapid assessment system available in the marketplace. This technology will be deployed in medical
clinics to provide MedX’s non-invasive skin scanning technology to physicians who will be able to have a dermatologist assess their patients’ suspicious
moles or lesions remotely,” said Scott Spearn, President of MedX. “DermSecure™ clearly offers great benefits to patients and primary care physicians by
working with dermatologists, leveraging their skills. DermSecure™ is a Software-as-a-Service revenue model, with recurring revenue growth – a key
development for MedX,” noted Mr. Spearn.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™
telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which
MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented
technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software
then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada,
FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures
and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain.
www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forwardlooking
statements involve risks and uncertainties. Actual events could differ from those projected herein and depend on a number of factors including the
success of the Company’s sales strategies.


CONTACT:


MedX Health Corp
Scott Spearn, 905-670-4428
President
or
Media Relations
Deborah Thompson, 416-918-9551
dthompson@medxhealth.com

!
Thumb 8020 monitor 200 200  png

8020 Admin

9 months

8020 Admin posted a press release MedX Health Corp. Announces Second Quarter 2018 Results in MEDX HEALTH CORP.

MISSISSAUGA, Ontario--(BUSINESS WIRE)--August 23, 2018--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results
for the three and six months ended June 30, 2018, which are also available on SEDAR (www.sedar.com).


The Company reported revenue of $405,707 for the three months ended June 30, 2018, a 71.3% increase over revenue of $236,892 for the three months
ended June 30, 2017. Revenues from the Company’s SIAscopy technology were $210,951 for the quarter, a 181% increase over the 2017 three-month
period. Sales from the Company's therapeutic laser line of $194,756 represented an increase of 20% over the comparable 2017 period. The Company
reported a loss for the three months ended June 30, 2018 of $1,579,245 or $0.01 per share compared with a loss of $403,631, or $0.00 per share for the three
months ended June 30, 2017. The second quarter loss includes a $928,576 non-cash expense recorded in respect of share options granted during the period
and $252,245 of expenditures related to developing its telemedicine platform and upgrading its SIAscope technology.


For the six months ended June 30, 2018, the Company reported revenue of $631,829, 32.5% higher than revenue of $476,702 for the six months ended June
30, 2017. The Company reported a loss of $2,251,397, or $0.02 per share for the six months ended June 30, 2018, compared with a loss of $751,490, or
$0.01 per share for the six months ended June 30, 2017. Included in the six-month expenses are $371,245 of costs related to the telemedicine platform
development and SIAscope upgrades, in addition to $933,968 of non-cash expenses recorded in the first half of 2018 in respect to share options granted.


“We are pleased with our progress in the second quarter, with strong revenue from SIAscopy driven by the launch of our product in Spain and a solid 20%
increase in sales of our therapeutic lasers,” commented Rob von der Porten, CEO of MedX. “We are currently preparing for the launch of our proprietary
telemedicine platform in Ontario and are working with our international marketing partners for telemedicine launches in a number of markets this year. We
believe that these initiatives will lead to significant revenue growth going forward. While spending on the development of our telemedicine platform and
other product enhancements has impacted our costs in the short-term, we will have the market-leading product for remote scanning and analysis of
potentially dangerous moles and lesions, benefitting patients and healthcare systems; and for MedX will provide increased revenue from these recurringrevenue
telemedicine initiatives.”


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology that is imbedded
in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™,
and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and
lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles
or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the
European Union and Turkey. MedX also designs, manufactures and distributes quality laser and light therapy technologies to provide drug free and noninvasive
treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forwardlooking
statements involve risks and uncertainties. Actual events could differ from those projected herein and depend on a number of factors including the
success of the Company’s sales strategies.


CONTACT:


MedX Health Corp.
Rob von der Porten, 905-670-4428 ext 226
CEO
or
Media Relations
Deborah Thompson, 416-918-9551
dthompson@medxhealth.com

!
Thumb 8020 monitor 200 200  png

8020 Admin

9 months

8020 Admin posted a press release MedX Health Corp. Announces Dermatologist Dr. Trevor Champagne, from Toronto’s Women's College Hospital, has Joined Medical Advisory Board in MEDX HEALTH CORP.

MISSISSAUGA, Ontario--(BUSINESS WIRE)--August 9, 2018--MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that Dr. Trevor
Champagne, Clinician in Quality and Innovation at Toronto’s Women's College Hospital, has joined its Medical Advisory Board. He is a board certified
dermatologist in Canada and the US.


“We are very pleased to have Dr. Champagne join our Medical Advisory Board as he brings unique skill sets, including expertise in Artificial Intelligence,
virtual care and teledermatology, that are ideal in assisting MedX to more efficiently and quickly reach larger global markets,” said Scott Spearn, President
of MedX. “Dr. Champagne has been using our SIAscopy technology and has already provided valuable input and clinician perspective into the telemedicine
platform we are developing and releasing shortly.”


"The ability for a health care technology to succeed at creating a viable artificial intelligence product depends on both the quality of the product and the
company's ability to understand the safest, most effective way to use it. I think MedX has both,” said Dr. Champagne.


Dr. Champagne has a Bachelor in Mathematics in Computer Science from the University of Waterloo and a B.Sc. in Molecular Biology and Biochemistry
from Simon Fraser University. He received his MD degree from the University of Western Ontario and is a graduate of the University of Toronto
Dermatology residency program. He is a Lecturer in the Division of Dermatology at the University of Toronto.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology that is imbedded
in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™,
and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and
lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles
or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the
European Union and Turkey. MedX also designs, manufactures and distributes quality laser and light therapy technologies to provide drug free and noninvasive
treatment of tissue damage and pain. www.medxhealth.com.


CONTACT:


MedX Health Corp
Scott Spearn, President
905 670 4428 ext 226
or
Media Relations
Deborah Thompson
DThompson@medxhealth.com
416-918-9551

!
Thumb 8020 monitor 200 200  png

8020 Admin

9 months

8020 Admin posted a press release MedX Health Corp. Announces First Quarter 2018 Result in MEDX HEALTH CORP.


MISSISSAUGA, Ontario--(BUSINESS WIRE)--May 29, 2018--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three
months ended March 31, 2018, which are also available on SEDAR (www.sedar.com).


The Company reported revenue of $226,122 for the three months ended March 31, 2018, compared with revenue of $239,810 for the three months ended March 31,
2017. Revenues from SIAscopy of $39,236 were 18% higher than the 2017 three-month period, while sales from the Company's therapeutic laser line of $186,886 were
lower than in the prior year. The Company reported a loss for the three months ended March 31, 2018 of $672,154 or $0.01 per share compared with a loss of $347,859,
or $0.00 per share for the three months ended March 31, 2017.


“Our revenue for the first quarter was lower than we had been anticipating, as the shipment of a $120,000 order that we received mid-quarter ended up being shipped
just after quarter end due to delays by our customer,” noted Rob von der Porten, CEO of MedX. “We are adding to our marketing efforts to build the laser sales and
preparing for the launch of our new telemedicine platform that will be ready for marketing this summer. Through the collaborations with our well respected Advisory
board members, such as U.S. based Dr. Dan Siegel and UK based Dr. Joe Walls and Dr. Per Hall, we are increasingly encouraged that our SIAscopy technology
integrated into a telemedicine platform will move the company into the forefront of remote scanning and analysis of potentially dangerous moles and lesions. The
investment in our technology and business development efforts have increased costs for the quarter, however non-recurring expenses represent approximately half of
the increase in the loss for the quarter over last year.”


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology that is imbedded in its
products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and
MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain
free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds.
These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also
designs, manufactures and distributes quality laser and light therapy technologies to provide drug free and non-invasive treatment of tissue damage and pain.
www.medxhealth.com.


CONTACT:


MedX Health Corp


Rob von der Porten, CEO
905-670-4428 ext 226
or
Media Relations
Deborah Thompson
Deborah@dt-communications.ca
416-918-9551

!
Thumb 8020 monitor 200 200  png

8020 Admin

9 months

8020 Admin posted a press release Academy of Dermatology joins MedX’s Medical Advisory Board in MEDX HEALTH CORP.

Dr. Daniel Siegel, Professor of Dermatology and former President of the American


MISSISSAUGA, Ontario--(BUSINESS WIRE)--May 23, 2018--MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that Dr.
Daniel Siegel, Clinical Professor of Dermatology at SUNY Downstate in Brooklyn, New York, and a former President of the
American Academy of Dermatology has joined its Medical Advisory Board.
“Daniel’s academic and practical business experience is impressive, including his expertise as a health policy and reimbursement
specialist. His many skills will help MedX develop a strong launch platform for the US market where we see significant growth
opportunities,” said Rob von der Porten, CEO of MedX.
“I am very pleased to be joining MedX’s Medical Advisory Board and I look forward to assisting the company execute their plans for
the U.S. market,” said Dr. Siegel. “MedX’s non-invasive SIAscope technology allows dermatologists to make accurate assessments of
potential life-threatening melanomas because of their unique imaging technology,” he added.
Dr. Siegel noted that “tele-dermatology has been slow to catch on because of its poor image quality, but with MedX’s clear
dermascopic view combined with four additional views 2 mm below the skin’s surface, it’s as close to having the patient in front of
you as I have seen.”


Dr. Siegel received his medical degree from Albany Medical College in New York, and completed his residency in dermatology at
Parkland Memorial Hospital in Dallas, Texas. He then pursued a fellowship in Mohs Micrographic Surgery and Dermatologic Surgery
at Baylor College of Medicine in Houston, Texas. He also earned a Master of Science degree in management and policy from the W.
Averell Harriman School for Management and Policy, State University of New York at Stony Brook.


Dr. Siegel has published more than 100 articles and book chapters in major medical journals and textbooks. He is a reviewer, editor,
and/or advisor for many of the major dermatology journals.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy
technology that is imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO
13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology
utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its
software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds.
These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the
European Union and Turkey. MedX also designs, manufactures and distributes quality laser and light therapy technologies to provide
drug free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


CONTACT:
MedX Health Corp.
Rob von der Porten, CEO
905-670-4428 ext 226
or
Media Relations
Deborah Thompson
DThompson@medxhealth.com
416-918-9551

!

MedX Health Corp.

lockPrivate Group

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™,...

people10 Members       (0)

Corporate Profile
Group Admins:
  • Thumb 8020 monitor 200 200  png
  • Thumb no photo
  • Thumb no photo
Request Membership


MedX Health Corp.

lockPrivateGroup

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAs......

people10 Members       (0)

Thumb 8020 monitor 200 200  png

8020 Admin

22 hours

8020 Admin posted a press release MedX Health and Sanitas Spain Announce a Large-Scale Skin Cancer Screening Initiative in Spain Using MedX's DermSecure(TM) Technology in MEDX HEALTH CORP.

MISSISSAUGA, Ontario


MedX Health Corp. (“MedX”) (TSX-V:MDX) announces that it has partnered with SANITAS, a specialist in healthcare and well-being services in Spain, to conduct a skin cancer screening initiative. According to recent studies, Spain, with its warm and sunny climate has experienced a 50% increase in skin cancer rates over the last decade. It is the most common form of cancer in women between the age of 25 and 29, followed by breast cancer, and the most common in men between the age of 30 and 35, ahead of lung and colon cancer.


MedX, with its Spanish distributor (OncoTech), has partnered with SANITAS, who will target twelve of SANITAS’s multi-national company customers, with up to 3,000 patient scans to be taken using MedX’s DermSecure™, to assess the benefits of such an initiative to SANITAS, its clients and the Spanish healthcare system. Upon completion, SANITAS will consider a significant expansion of this program. Dr. Miguel Marine Blanco, Director of Strategic Alliances for SANITAS commented, “With the increase in skin cancer rates in Spain we felt being able to offer our members skin cancer screening with the best screening technology available would be well received by our members.”


Sanitas offers its clients products and services adapted to people’s real needs at each stage of their lives through an integral healthcare model that includes: medical insurance, hospitals and multi-speciality centres, well-being centres, dental clinics, other health services and services for the care of the elderly. Sanitas forms part of Bupa, a leading international healthcare company, which serves over 15.7 million insurance policy holders, 15 million patients and 23,000 elderly people.


Mr. Frank Melendez, OncoTech’s President stated, “It is an honour to work with SANITAS and their multi-national customers. They truly wish to deliver the best possible care to their members which speaks to their success. We are looking forward to the results of this pilot and to further expand this program in the future.”


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com


About SANITAS


Sanitas is a specialist in healthcare and well-being services in Spain. It offers its clients products and services adapted to people’s real needs at each stage of their lives through an integral healthcare model that includes: medical insurance, hospitals and multi-speciality centres, well-being centres, dental clinics, other health services and services for the care of the elderly.


It has 10,859 employees; it has a medical team made up of over 40,000 specialists and 1,200 associated medical centres, in addition to its own service, formed by 4 hospitals, 20 multi-speciality medical centres, 16 well-being centres, 180 dental clinics, 47 homes for the elderly, 17 of them with day centre services and 5 independent day centres.


Sanitas forms part of Bupa, a leading international healthcare company, which serves over 15.7 million insurance policy holders, 15 million patients and 23,000 elderly people.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.


View source version on businesswire.com: https://www.businesswire.com/news/home/20190617005235/en/



Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229



!
Thumb 8020 media relations

Media Relations posted an update in MEDX HEALTH CORP.

2 months

Mike Druhan on the competitive advantages of MedX's (TSXV: MDX) skin cancer diagnosis technology

!
Thumb 8020 monitor 200 200  png

8020 Admin

2 months

8020 Admin posted a press release MedX Health Corp. Announces Non-Brokered Private Placement in MEDX HEALTH CORP.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it has obtained Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 15,625,000 units at $0.16 per unit (“Unit”), to raise up to $2,500.000. Each Unit will be comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.25, exercisable for a period of two years from the date of issue. Closing of the Placement, which will take place in tranches, will be subject to receipt of subscriptions and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. Qualified Agents may receive commissions in respect of subscriptions introduced by them by way of cash equal to 6% of funds so introduced, and issuance of agent’s warrants (“Agent’s Warrant(s)”) equal in number to 6% of the number of units so subscribed for. Each Agent’s Warrant, which is non-transferable, will be exercisable to acquire one Unit at $0.16 per Unit, at any time during the period of two years following the Closing. The first Closing of this private placement has taken place on April 26, 2019, to raise $282,600 by issuance of 1,766,250 Units. In connection with the first Closing, a cash commission of $12,960 was paid and 79,350 Agent’s Warrants were issued.


Following this Closing, MedX has 139,782,651 common shares issued and outstanding.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.




Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229


Media Relations
Deborah Thompson
dthompson@medxhealth.com
416-918-9551


!
Thumb 8020 monitor 200 200  png

8020 Admin

2 months

8020 Admin posted a press release MedX Health Signs Exclusive Distribution Agreement to Launch DermSecure(TM) in Brazil, where Skin Cancer is Prevalent in MEDX HEALTH CORP.

MISSISSAUGA, Ontario


MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that it has signed an Exclusive Distribution Agreement with CBD Vida (“Vida”), to launch a comprehensive, ease-of-access skin scanning/assessment program throughout Brazil, using MedX’s DermSecureTM Telemedicine platform.


This exclusive distribution agreement is a natural progression of the earlier Memorandum of Understanding with Vida “because their reach in the Brazilian marketplace is robust and extensive,” said Scott Spearn, President & CEO of MedX. Mr. Spearn said that Vida has agreed to pay for all regulatory, marketing and distribution expenses related to the launch. Mr. Spearn also noted that the agreed performance levels on the part of Vida further reinforce their commitment to the commercial success of this agreement.


“Vida is 100% committed to this innovative screening platform. There are almost 212 million Brazilian people, where skin cancer is the most common form of cancer,” said Camata Candello, Vida’s CEO. There were over 100,000 cases of skin cancer diagnosed in Brazil between 2016 and 2017, and almost 6,000 were melanomas, the most aggressive form of the disease that has a high mortality rate. “This cancer does not need to be lethal and can be prevented through early detection. I believe this is a game changer. Brazil is a huge market opportunity for us,” continued Mr. Candello.


“We are always looking for solutions that are innovative and meaningful to invest in; as well they must have a major impact on the Brazilian people we serve. I can genuinely say that MedX’s DermSecureTM meets those criteria, and then some,” said Camata Candello.


“MedX’s DermSecure TM is a perfect solution for early detection of skin cancer," he said. “We are deeply aligned with the largest distributors of hospital equipment in Brazil, we will be distributing throughout the national territory of Brazil, offering MedX’s rapid skin assessment technology to Public and Private Hospitals, Medical Clinics, Pharmacies, Dermatologists and Oncologists. We believe this technology will have a major impact on public health, and as such have implemented a marketing plan to provide the equipment to Brazil's public health network for a fee in order to speed the rate of deployment throughout Brazil,” stated Camata Candello, Vida’s CEO.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


About CBD Vida


The founders of CBD Vida Canada, combined with their CBD Vida LTDA partners in Brazil, form a partnership that brings decades of professional business development, training and experience. CBD Vida LTDA’s business relationships in Brazil are extensive and cover pharmaceuticals, medical clinics, and pharmacies, legal, regulatory, governmental, and private industry. These relationships provide a synergy between Brazil & Canada that will ensure expedited market entry for this life saving solution.


The partners understand the importance of Brazil on the world market, with it being the second largest importer of medical devices in the world. CBD Vida’s relationship with MedX and their rapid skin assessment solution, combined with their corporate & business experiences, will give the Brazilian population an opportunity to dramatically reduce the mortality rate currently being experienced by late the late detection skin cancer. CBD Vida LTDA has the capability and commitment to open the Brazilian market rapidly and help our fellow Brazilians with this preventable cancer.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.




Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229

Jean Guy Bourguignon, President and COO
CBD Vida Canada
613-406-6473

Media Relations
Deborah Thompson
416-918-9551



!
Thumb 8020 monitor 200 200  png

8020 Admin

4 months

8020 Admin posted a press release MedX Health Corp. Announces Private Label Distributor Agreement for Selected Therapeutic Laser Products with Richmar in US in MEDX HEALTH CORP.

MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed an agreement with Richmar, a Compass Health Brands Company, to manufacture and supply selected Private Label Laser and Light products to Richmar for the US rehabilitation market.


“We are very pleased that we are moving forward with Richmar. We believe their strong presence in the US, with a quality distribution network across the US will help MedX open channels to our Therapeutic Laser products and contribute to revenue growth in this large and important marketplace,” said Scott Spearn, President & CEO of MedX.


Mr. Spearn explained that MedX will provide under Private Label a number of its laser and SLD based products to Richmar, which is headquartered in Saint Louis, MO, with other facilities located throughout the US. “We are ramping up production and are set to begin delivering our specified reliable, high-quality, Therapeutic Laser products that service physicians and clinicians,” Mr. Spearn added. Target markets include chiropractors, physical therapists, athletic trainers, and other qualified healthcare professionals who wish to decrease pain and restore function to their patients.


According to a 2017 report from Grand View Research, the United States is experiencing an increasing prevalence of degenerative diseases, an expanding geriatric population, as well as a growing number of trauma patients; who will all require physical rehabilitation. “It is important to Richmar that we have the appropriate tools and technologies to assist these populations,” noted Ryan Moore, Senior Vice President, Therapy, at Richmar. “Our partnership with MedX will help ensure that we are equipped to provide clinicians with what they need to drive better outcomes and improve patients’ lives.”


About MedX Health Corp.


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


About Richmar


Since 1968, Richmar has provided clinicians with the means to treat musculoskeletal and soft tissue inflammation. A Compass Health Brands company, Richmar is a leading manufacturer and distributor of a diverse line of high-quality medical devices and accessories for the physical therapy, chiropractic, and athletic training markets. A relentless innovator, Richmar features a growing list of products which serve the needs of clinicians treating musculoskeletal and soft tissue disorders. Among Richmar's product portfolio are such modalities as electrotherapy, combination, laser, diathermy, ultrasound, and their corresponding consumables. Richmar's popular brands include Winner EVO Series™, HydraTherm™, HydraHeat™, TheraTouch®, AutoSound®, InTENSity®, StrengthTape®, and SubZero®. Visit richmarweb.com.


About Compass Health Brands


Compass Health Brands® manufactures and distributes a broad range of innovative and high-quality homecare, rehabilitation, light therapy and pain management products that enable consumers to live healthier, more independent lives. The company markets its products to both professional and consumer sectors. Consumer brands include Carex®, AccuRelief™, Apex®, TheraLite™, Bed Buddy®, STRENGTHTAPE® and TheraMed® and are sold through drugstore chains, drug wholesalers, mass merchants, and grocery retailers. Professional brands include ProBasics™, Roscoe Medical®, Meridian Medical®, InTENSity®, and Richmar® which are sold through a professional independent dealer/distributor network.




Scott Spearn, President & CEO, MedX
905 670 4428 ext 226


Media Relations
Deborah Thompson
DThompson@medxhealth.com
M: 416-918-9551


!
Thumb 8020 monitor 200 200  png

8020 Admin

5 months

8020 Admin posted a press release MedX Health Signs MOU to Launch DermSecure(TM) in Brazil in MEDX HEALTH CORP.

MISSISSAUGA, Ontario


MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed a Memorandum of Understanding with CBD Vida LTDA, who plans to launch an ease-of-access skin scanning/assessment program throughout Brazil, using MedX’s DermSecureTM. Telemedicine platform.


"There is a significant opportunity for MedX’s skin imaging technology in Brazil, as skin cancer is the most common type of cancer in Brazil,” stated Fabio Camata Candello, CBD Vida LTDA’s CEO. More than one hundred thousand new cases of skin cancer were recorded in Brazil between 2016 and 2017, according to the Brazilian Cancer Institute, and almost 6,000 were classified as melanoma, an aggressive form of the disease that can spread to other parts of the body. A recent study shows that Brazilian melanoma patients experienced a lower survival rate than the current worldwide average. The high prevalence of advanced cases reinforces the importance of local strategies to diagnose melanomas in the early stages, and to treat it definitively. “MedX’s DermSecureTM telemedicine platform and advanced SIAscopy imaging technology is a perfect solution for early detection," further noted Mr. Candello.


"CBD Vida LTDA’s experience in marketing medical devices and health solutions in the Brazilian market, as well as their deep connectivity with major pharmacies and medical clinics will be a big benefit as they enter into this large market, and we are delighted to be partnering with them,” noted Scott Spearn, President & CEO of MedX “


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


About CBD Vida LTDA


The founders of CBD Vida Canada, combined with their CBD Vida LTDA partners in Brazil form a partnership that brings decades of professional business development, training and experience. CBD Vida LTDA’s business relationships in Brazil are extensive and cover pharmaceuticals, medical clinics, and pharmacies, legal, regulatory, governmental, and private industry. These relationships provide a synergy between Brazil & Canada that will ensure expedited market entry for this life saving solution.


The partners understand the importance of Brazil on the world market, with it being the second largest importer of medical devices in the world. CBD Vida LTDA’s relationship with MDX Health and their rapid skin assessment solution, combined with their corporate & business experiences, will give the Brazilian population an opportunity to dramatically reduce the mortality rate currently being experienced by late the late detection skin cancer. CBD Vida LTDA has the capability and commitment to open the Brazilian market rapidly and help our fellow Brazilians with this preventable cancer.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.




Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229



!
Thumb 8020 monitor 200 200  png

8020 Admin

5 months

8020 Admin posted a press release MedX Health Corp. Announces Private Placement Closing in MEDX HEALTH CORP.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

January 29, 2019


MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX) announces that, pursuant to a non-brokered Private Placement Offering (the “Placement Offering”), it has completed an initial Closing of 2,962,500 Units on January 28, 2019, to raise $474,000 from accredited investors pursuant to a Private Placement Offering originally announced on November 23, 2018. Each Unit, priced at $0.16, comprises one fully paid common share and one share purchase warrant; each warrant entitles the holder to purchase one additional share at a price of $0.35 during the period up to three years from the closing date of the placement. The securities issued as a result of the Placement Offering will be restricted from trading for four months following each Closing. The Placement Offering is still open to subscribers, and further subscriptions may be accepted for further Closings. This Closing, and any further Closing of the Placement Offering, is subject to all relevant regulatory and other consents and approvals, including acceptance by the TSX Venture Exchange.


Following this Closing, MedX has 138,016,401 common shares issued and outstanding.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.




Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229


Media Relations
Deborah Thompson
dthompson@medxhealth.com
416-918-9551


!
Thumb year end 2017

Darren Stewart posted an update in MEDX HEALTH CORP.

5 months

Just thought I would share.

!
Thumb 8020 monitor 200 200  png

8020 Admin

6 months

8020 Admin posted a press release MedX Health Announces That Dr. Bruno Battistini, an Accomplished Canadian-Based Health Care Researcher Has Joined Its Medical Advisory Board in MEDX HEALTH CORP.

MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that Dr. Bruno Battistini, a Canadian-based health care researcher and medical business advisor has joined MedX’s Medical Advisory Board.


“While the members of our Medical Advisory Board to date are esteemed physicians and researchers specializing in skin cancer and other Dermatological conditions, Dr. Battistini complements the group by providing a breadth of experience dealing with policy, and bridging the gap with government, health care agencies and providers to gain access to Canadian markets,” said Scott Spearn, CEO of MedX. “His understanding of the dynamics in the Private/Public market will be of great benefit as we launch our skin assessment platform, DermSecure™, across Canada.”


“I am genuinely impressed with MedX’s complete solution for skin cancer screening,” noted Dr. Battistini. “Not only is the scanning technology so unique, offering the ability to image and highlight pathophysiology images below the skin, but the development of an internet-based platform that can provide widespread access to the public for fast and easy assessment will be a driver for reducing wait times and improved outcomes in a world that is experiencing increasing incidence of skin cancer and other skin conditions. There is no reason why MedX’s technology cannot assist our health care system and streamline the services to meet patients’ needs when it has already been implemented in other countries and working successfully for many years. The translation of knowledge and implementation of innovation is key to the sustainability of our healthcare system, considering our aging population,” noted Dr. Battistini


Dr. Battistini is an accomplished health care researcher, former professor of medicine, entrepreneur, senior executive and administrator whose background in pharmacology has resulted in a broad range of experience working with universities, government agencies and health foundations to understand how policies are developed such that companies can access markets with innovative products to improve the health care system and benefit patients and the general population. He has engaged with many Canadian companies, all in major and smaller provinces in guiding the development, acknowledgement, adoption and commercializing of products.


About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.




Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229


Media Relations
Deborah Thompson
dthompson@medxhealth.com
416-918-9551


!
Thumb 8020 monitor 200 200  png

8020 Admin

7 months

8020 Admin posted a press release MedX Signs MOU to Launch DermSecure(TM) in the Netherlands in MEDX HEALTH CORP.

MISSISSAUGA, Ontario



MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed a Memorandum of Understanding with a consortium of Dutch companies that will be launching an easy-access skin scanning/assessment program in the Netherlands, using MedX’s SIAscopy and DermSecureTM technologies. The consortium will integrate DermSecureTM with their existing platforms, which includes a suite of software applications used by a large majority of general practitioners in the Netherlands, and will build awareness campaigns through established healthcare initiatives and programs.


“The Dutch team is impressed with SIAscopy’s unique scanning technology, and the ability to seamlessly integrate our DermSecureTM platform into their suite of medical software applications that are used by more than 4,500 physicians in the Netherlands makes it a natural fit,” noted Scott Spearn, MedX’s President and CEO. “The broad reach of telemedicine from this many potential locations, with DermSecureTM providing the highest quality tools for the assessment by a team of trained Dermatologists, and the awareness built through their marketing relationships can enable the group to meet their objective of a truly national scanning/assessment program in the Netherlands, where there is a focus on cancer prevention and early screening.”


Pieter Severijns, Director of IvPG, one of the partners in this project and a company involved in programs and initiatives to improve healthcare in the Netherlands through the internet, noted “We have the ability through our programs to make people aware about the risks of melanoma, and allow those with higher risk or suspicious moles to easily access skin scanning and assessment by our top Dermatologists using DermSecureTM, through the large network of scanning centres that will be available to them.”


MedX will be working during the coming months to integrate its platform with those of its partners, while physicians are recruited to include DermSecureTM and MedX’s SIAscopy devices in their practices, and selected Dermatologists trained to provide timely assessment.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.


View source version on businesswire.com: https://www.businesswire.com/news/home/20181127005308/en/



Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229


Media Relations
Deborah Thompson
dthompson@medxhealth.com
416-918-9551



!
Thumb 8020 monitor 200 200  png

8020 Admin

7 months

8020 Admin posted a press release MedX Launches Strategic Artificial Intelligence Initiative in MEDX HEALTH CORP.

MISSISSAUGA, Ontario 



MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it is initiating the development of an Artificial Intelligence Engine with leading dermatologists and its technology partner, Blanc Labs, that will work in conjunction with its existing DermSecureTM screening platform. MedX has an opportunity to leverage Artificial Intelligence to create a unique assessment support tool allowing Dermatologists to more accurately assess suspicious moles and lesions from remote locations.


MedX’s advanced SIAscopy imaging technology lends itself to AI because of the specialized image capture above and below the skin’s surface. “SIAscopy is the only imaging technology that provides a dermascopic image along with four additional proprietary pathophysiology views 2 mm below the skin’s surface, produced in a consistent format, and we believe this large amount of data will increase the accuracy of our AI engine” said Scott Spearn, MedX’s President and CEO.


MedX has been working closely with its Scientific Medical Advisory Board (“SMAB”) to launch an AI strategy that will complement DermSecureTM and current assessment protocols. Dr. Trevor Champagne commented, “MedX has got the AI questions right. The question that AI needs to address is not what is a melanoma, but what is not a melanoma? What do we need to concentrate on with our biopsies and diagnosis? What can we safely exclude from this pool of potentially dangerous lesions? MedX’s thinking around AI is extremely important and I look forward to collaborating with them on this important advancement in the field of Dermatology.”


Dr. Joe Walls, also on MedX’s SMAB further noted “I wrote my thesis on SIAscopy and have been deeply involved in analyzing SIAscopic images in my professional practice. I think the advanced standardized images that SIAscopy produces will deeply enhance the AI process. AI only works when you have quality input and SIAscopy produces unique images not found in other imaging technologies,” noted Dr. Walls.


MedX looks forward to taking the next step with Blanc Labs on this important strategic initiative. “Adding AI features to the DermSecureTM platform is a natural evolution for this advanced medical imaging solution,” noted Dariush Zomorrodi, Blanc Lab’s Chief Innovation Officer, who has been collaborating with MedX on the development of DermSecureTM. “We will apply Machine Learning technology to a collection of images and diagnostic data. With the increase of data size, over time, the Deep Learning algorithm will enable the platform to deliver a highly accurate assessment tool to Dermatologists, and we are very excited to continue innovating with MedX, pushing the boundaries, and making an impact on the early detection of skin cancer.”


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.




Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229


Media Relations
Deborah Thompson
dthompson@medxhealth.com
416-918-9551



!
Thumb 8020 monitor 200 200  png

8020 Admin

8 months

8020 Admin posted a press release MedX Health Announces That Dr. Eggert Stockfleth, Director of the University Department of Dermatology at St. Josef-Hospital in Bochum, Germany Has Joined Its Medical Advisory Board in MEDX HEALTH CORP.

MISSISSAUGA, Ontario



MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that Dr. Eggert Stockfleth, Director of the University Department of Dermatology at St. Josef-Hospital in Bochum, Germany has agreed to join MedX’s Medical Advisory Board. Dr. Stockfleth was previously the Director of the Skin Cancer Center in Berlin.


“The addition of Dr. Stockfleth to our Medical Advisory Board completes our group of highly accomplished physicians from around the world. They are respected thought leaders located in our targeted markets. We are very fortunate to have access to Dr. Stockfleth’s knowledge and expertise,” said Scott Spearn, CEO of MedX.


“MedX’s non-invasive skin cancer scanning technology is ground-breaking and I am honored to be a member of such an esteemed group of physicians,” Dr. Stockfleth said. “I see first-hand how MedX’s technology is a game-changer in early detection of skin cancers,” he added. He noted that his clinic in Bochum receives in excess of 800 calls per day with respect to dermatological issues and has a capacity to handle only about half of the inquiries.


Dr. Stockfleth’s research on dermatology, oncology and in particular, skin cancer, has been extensively published in peer-reviewed journals. He has contributed to the Journal of Infectious Diseases, International Journal of Cancer, Journal of Investigative Dermatology and The Lancet. He is also the former European President of Skin Care in Organ Transplant Patients Network (SCOPE). In 2008 he was one of the founders of the European Skin Cancer Foundation, which assists in developing and providing standardized treatments on a European level. Dr. Stockfleth graduated from the University of Hamburg and is a Jung-Foundation scholar.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.




MedX Health Corp
Scott Spearn, 905-670-4428 ext 229
President and CEO
or
Media Relations
Deborah Thompson, 416-918-9551
dthompson@medxhealth.com



!
Thumb 8020 monitor 200 200  png

8020 Admin

9 months

8020 Admin posted a press release MedX Launches Its DermSecure™ Telemedicine Platform in MEDX HEALTH CORP.

MISSISSAUGA, Ontario--(BUSINESS WIRE)--September 4, 2018--MedX Health Corp. (“MedX”) (TSX-V:MDX) announced today that it is launching
DermSecure™, its telemedicine platform, in six Ontario clinics. MedX will begin rolling out DermSecure™ across Ontario and subsequently Canada while
finalizing its introduction into a number of international markets.


It is currently working on a DermSecure™ roll-out with its Spanish distribution partner as well as plans for the US, Mexico, and the Netherlands. MedX’s DermSecure™ has been built to the leading data repository standards to allow for integrationwith Electronic Medical Record (EMR’s) systems. Its development roadmap includes the addition of features and functions to the DermSecure™ platformthat will be released on a regular basis.


“DermSecure™ is a secure telemedicine platform, coupled with MedX’s innovative imaging technology, SIAscopy, that will provide dermatologists and
patients access to the most advanced mole and lesion rapid assessment system available in the marketplace. This technology will be deployed in medical
clinics to provide MedX’s non-invasive skin scanning technology to physicians who will be able to have a dermatologist assess their patients’ suspicious
moles or lesions remotely,” said Scott Spearn, President of MedX. “DermSecure™ clearly offers great benefits to patients and primary care physicians by
working with dermatologists, leveraging their skills. DermSecure™ is a Software-as-a-Service revenue model, with recurring revenue growth – a key
development for MedX,” noted Mr. Spearn.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™
telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which
MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented
technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software
then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada,
FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures
and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain.
www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forwardlooking
statements involve risks and uncertainties. Actual events could differ from those projected herein and depend on a number of factors including the
success of the Company’s sales strategies.


CONTACT:


MedX Health Corp
Scott Spearn, 905-670-4428
President
or
Media Relations
Deborah Thompson, 416-918-9551
dthompson@medxhealth.com

!
Thumb 8020 monitor 200 200  png

8020 Admin

9 months

8020 Admin posted a press release MedX Health Corp. Announces Second Quarter 2018 Results in MEDX HEALTH CORP.

MISSISSAUGA, Ontario--(BUSINESS WIRE)--August 23, 2018--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results
for the three and six months ended June 30, 2018, which are also available on SEDAR (www.sedar.com).


The Company reported revenue of $405,707 for the three months ended June 30, 2018, a 71.3% increase over revenue of $236,892 for the three months
ended June 30, 2017. Revenues from the Company’s SIAscopy technology were $210,951 for the quarter, a 181% increase over the 2017 three-month
period. Sales from the Company's therapeutic laser line of $194,756 represented an increase of 20% over the comparable 2017 period. The Company
reported a loss for the three months ended June 30, 2018 of $1,579,245 or $0.01 per share compared with a loss of $403,631, or $0.00 per share for the three
months ended June 30, 2017. The second quarter loss includes a $928,576 non-cash expense recorded in respect of share options granted during the period
and $252,245 of expenditures related to developing its telemedicine platform and upgrading its SIAscope technology.


For the six months ended June 30, 2018, the Company reported revenue of $631,829, 32.5% higher than revenue of $476,702 for the six months ended June
30, 2017. The Company reported a loss of $2,251,397, or $0.02 per share for the six months ended June 30, 2018, compared with a loss of $751,490, or
$0.01 per share for the six months ended June 30, 2017. Included in the six-month expenses are $371,245 of costs related to the telemedicine platform
development and SIAscope upgrades, in addition to $933,968 of non-cash expenses recorded in the first half of 2018 in respect to share options granted.


“We are pleased with our progress in the second quarter, with strong revenue from SIAscopy driven by the launch of our product in Spain and a solid 20%
increase in sales of our therapeutic lasers,” commented Rob von der Porten, CEO of MedX. “We are currently preparing for the launch of our proprietary
telemedicine platform in Ontario and are working with our international marketing partners for telemedicine launches in a number of markets this year. We
believe that these initiatives will lead to significant revenue growth going forward. While spending on the development of our telemedicine platform and
other product enhancements has impacted our costs in the short-term, we will have the market-leading product for remote scanning and analysis of
potentially dangerous moles and lesions, benefitting patients and healthcare systems; and for MedX will provide increased revenue from these recurringrevenue
telemedicine initiatives.”


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology that is imbedded
in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™,
and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and
lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles
or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the
European Union and Turkey. MedX also designs, manufactures and distributes quality laser and light therapy technologies to provide drug free and noninvasive
treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forwardlooking
statements involve risks and uncertainties. Actual events could differ from those projected herein and depend on a number of factors including the
success of the Company’s sales strategies.


CONTACT:


MedX Health Corp.
Rob von der Porten, 905-670-4428 ext 226
CEO
or
Media Relations
Deborah Thompson, 416-918-9551
dthompson@medxhealth.com

!
Thumb 8020 monitor 200 200  png

8020 Admin

9 months

8020 Admin posted a press release MedX Health Corp. Announces Dermatologist Dr. Trevor Champagne, from Toronto’s Women's College Hospital, has Joined Medical Advisory Board in MEDX HEALTH CORP.

MISSISSAUGA, Ontario--(BUSINESS WIRE)--August 9, 2018--MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that Dr. Trevor
Champagne, Clinician in Quality and Innovation at Toronto’s Women's College Hospital, has joined its Medical Advisory Board. He is a board certified
dermatologist in Canada and the US.


“We are very pleased to have Dr. Champagne join our Medical Advisory Board as he brings unique skill sets, including expertise in Artificial Intelligence,
virtual care and teledermatology, that are ideal in assisting MedX to more efficiently and quickly reach larger global markets,” said Scott Spearn, President
of MedX. “Dr. Champagne has been using our SIAscopy technology and has already provided valuable input and clinician perspective into the telemedicine
platform we are developing and releasing shortly.”


"The ability for a health care technology to succeed at creating a viable artificial intelligence product depends on both the quality of the product and the
company's ability to understand the safest, most effective way to use it. I think MedX has both,” said Dr. Champagne.


Dr. Champagne has a Bachelor in Mathematics in Computer Science from the University of Waterloo and a B.Sc. in Molecular Biology and Biochemistry
from Simon Fraser University. He received his MD degree from the University of Western Ontario and is a graduate of the University of Toronto
Dermatology residency program. He is a Lecturer in the Division of Dermatology at the University of Toronto.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology that is imbedded
in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™,
and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and
lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles
or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the
European Union and Turkey. MedX also designs, manufactures and distributes quality laser and light therapy technologies to provide drug free and noninvasive
treatment of tissue damage and pain. www.medxhealth.com.


CONTACT:


MedX Health Corp
Scott Spearn, President
905 670 4428 ext 226
or
Media Relations
Deborah Thompson
DThompson@medxhealth.com
416-918-9551

!
Thumb 8020 monitor 200 200  png

8020 Admin

9 months

8020 Admin posted a press release MedX Health Corp. Announces First Quarter 2018 Result in MEDX HEALTH CORP.


MISSISSAUGA, Ontario--(BUSINESS WIRE)--May 29, 2018--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three
months ended March 31, 2018, which are also available on SEDAR (www.sedar.com).


The Company reported revenue of $226,122 for the three months ended March 31, 2018, compared with revenue of $239,810 for the three months ended March 31,
2017. Revenues from SIAscopy of $39,236 were 18% higher than the 2017 three-month period, while sales from the Company's therapeutic laser line of $186,886 were
lower than in the prior year. The Company reported a loss for the three months ended March 31, 2018 of $672,154 or $0.01 per share compared with a loss of $347,859,
or $0.00 per share for the three months ended March 31, 2017.


“Our revenue for the first quarter was lower than we had been anticipating, as the shipment of a $120,000 order that we received mid-quarter ended up being shipped
just after quarter end due to delays by our customer,” noted Rob von der Porten, CEO of MedX. “We are adding to our marketing efforts to build the laser sales and
preparing for the launch of our new telemedicine platform that will be ready for marketing this summer. Through the collaborations with our well respected Advisory
board members, such as U.S. based Dr. Dan Siegel and UK based Dr. Joe Walls and Dr. Per Hall, we are increasingly encouraged that our SIAscopy technology
integrated into a telemedicine platform will move the company into the forefront of remote scanning and analysis of potentially dangerous moles and lesions. The
investment in our technology and business development efforts have increased costs for the quarter, however non-recurring expenses represent approximately half of
the increase in the loss for the quarter over last year.”


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology that is imbedded in its
products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and
MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain
free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds.
These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also
designs, manufactures and distributes quality laser and light therapy technologies to provide drug free and non-invasive treatment of tissue damage and pain.
www.medxhealth.com.


CONTACT:


MedX Health Corp


Rob von der Porten, CEO
905-670-4428 ext 226
or
Media Relations
Deborah Thompson
Deborah@dt-communications.ca
416-918-9551

!
Thumb 8020 monitor 200 200  png

8020 Admin

9 months

8020 Admin posted a press release Academy of Dermatology joins MedX’s Medical Advisory Board in MEDX HEALTH CORP.

Dr. Daniel Siegel, Professor of Dermatology and former President of the American


MISSISSAUGA, Ontario--(BUSINESS WIRE)--May 23, 2018--MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that Dr.
Daniel Siegel, Clinical Professor of Dermatology at SUNY Downstate in Brooklyn, New York, and a former President of the
American Academy of Dermatology has joined its Medical Advisory Board.
“Daniel’s academic and practical business experience is impressive, including his expertise as a health policy and reimbursement
specialist. His many skills will help MedX develop a strong launch platform for the US market where we see significant growth
opportunities,” said Rob von der Porten, CEO of MedX.
“I am very pleased to be joining MedX’s Medical Advisory Board and I look forward to assisting the company execute their plans for
the U.S. market,” said Dr. Siegel. “MedX’s non-invasive SIAscope technology allows dermatologists to make accurate assessments of
potential life-threatening melanomas because of their unique imaging technology,” he added.
Dr. Siegel noted that “tele-dermatology has been slow to catch on because of its poor image quality, but with MedX’s clear
dermascopic view combined with four additional views 2 mm below the skin’s surface, it’s as close to having the patient in front of
you as I have seen.”


Dr. Siegel received his medical degree from Albany Medical College in New York, and completed his residency in dermatology at
Parkland Memorial Hospital in Dallas, Texas. He then pursued a fellowship in Mohs Micrographic Surgery and Dermatologic Surgery
at Baylor College of Medicine in Houston, Texas. He also earned a Master of Science degree in management and policy from the W.
Averell Harriman School for Management and Policy, State University of New York at Stony Brook.


Dr. Siegel has published more than 100 articles and book chapters in major medical journals and textbooks. He is a reviewer, editor,
and/or advisor for many of the major dermatology journals.


About MedX


MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy
technology that is imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO
13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology
utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its
software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds.
These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the
European Union and Turkey. MedX also designs, manufactures and distributes quality laser and light therapy technologies to provide
drug free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.


CONTACT:
MedX Health Corp.
Rob von der Porten, CEO
905-670-4428 ext 226
or
Media Relations
Deborah Thompson
DThompson@medxhealth.com
416-918-9551

!